Protagonist Therapeutics, Inc 4

Insider William D. Waddill exercised options for 9,000 Protagonist Therapeutics (PTGX) shares and sold all 9,000 shares on June 10, 2026 under a 10b5‑1 plan, ending with 7,825 shares owned.

On June 10, 2026, Protagonist Therapeutics, Inc. insider William D. Waddill exercised two tranches of fully vested stock options to acquire a total of 9,000 shares of common stock at strike prices of $11.80 and $16.54 per share, then sold all 9,000 shares in a same‑day disposition at a weighted average price of $107.68 per share under a pre‑arranged Rule 10b5‑1 trading plan adopted on February 27, 2026. Specifically, he exercised options for 3,000 shares at $11.80 and 6,000 shares at $16.54, acquiring the shares and increasing his direct holdings intra‑day, and then sold 9,000 shares, generating gross proceeds of approximately $969,120 and leaving him with direct ownership of 7,825 shares of common stock following the transactions. The Form 4 notes that the sale price represents a weighted average of multiple trades executed between $107.02 and $108.00 per share, and confirms that the underlying stock options were fully vested at the time of exercise.

Filing Facts

CIK

1377121

Ticker

PTGX

Form

4

Source Type

sec

Accession

0001104659-26-073049

Alert Tier

6